Fig 1.
Plasma renin method comparison between Lumipulse® (Fujirebio®) and Liaison XL® (Diasorin®); A: correlation, B: Bland-Altman (Lumipulse® – Liaison XL).
Plasma aldosterone method comparison between Lumipulse® (Fujirebio®) and LC-MS/MS; C: correlation, D: Bland-Altman (Lumipulse® – LC-MS/MS). 24-hour urine aldosterone method comparison between Lumipulse® (Fujirebio®) and LC-MS/MS; E: correlation, F: Bland-Altman analysis (Lumipulse® – LC-MS/MS).
Fig 2.
Flow chart for the evaluation of primary aldosteronism blood criteria.
Patients were categorized into three groups: primary aldosteronism (PA), essential hypertension (EH), and other miscellaneous diseases. All samples were used for the method comparison, while only samples from PA and EH patients without renin-angiotensin-aldosterone system-interfering drugs were used for determining the PA cut-off.
Table 1.
Demographic characteristics of patients included for determining the ARR and PAC cut-off values.
Fig 3.
Flow chart for the evaluation of primary aldosteronism 24-hour urine aldosterone excretion.
Patients were categorized into three groups: primary aldosteronism (PA), essential hypertension (EH), and other miscellaneous diseases. All samples were used for the method comparison, while only samples from PA and EH patients without renin-angiotensin-aldosterone system-interfering drugs were used for determining the PA cut-off.
Table 2.
Demographic characteristics of patients included for determining the 24-hour urine aldosterone excretion cut-off values.
Fig 4.
Primary aldosteronism cut-off definition using Lumipulse® for the aldosterone-to-renin ratio (ARR).
A: Primary aldosteronism (PA) and essential hypertension (EH) ARR distribution, B: ARR ROC curve; for plasma aldosterone concentration (PAC), C: PA and EH PAC distribution, D: PAC ROC curve; for 24-hour urine aldosterone excretion (24UA), E: PA and EH 24UA distribution, F: 24UA ROC curve.
Table 3.
Performance of aldosterone-to-renin ratio (ARR) cut-off values for primary aldosteronism detection: primary aldosteronism versus essential hypertension patients using Lumipulse®.
Table 4.
Performance of basal plasma aldosterone concentration (PAC) cut-off values for primary aldosteronism detection: primary aldosteronism versus essential hypertension patients using Lumipulse®.
Table 5.
Performance of 24-hour urine aldosterone excretion (24UA) cut-off values for primary aldosteronism detection: primary aldosteronism versus essential hypertension patients using Lumipulse®.